Grupo para la caracterización molecular de las neoplasias hematológicas
Hospital Costa Del Sol
Marbella, EspañaPublicaciones en colaboración con investigadores/as de Hospital Costa Del Sol (18)
2023
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
2022
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
-
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538
-
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
Cancer, Vol. 128, Núm. 13, pp. 2441-2448
2021
-
Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
Leukemia, Vol. 35, Núm. 1, pp. 245-249
-
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Blood Cancer Journal, Vol. 11, Núm. 5
-
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Blood, Vol. 138, Núm. 17, pp. 1583-1589
2020
-
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158
-
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study
Cancer Medicine, Vol. 9, Núm. 22, pp. 8468-8479
2019
-
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Leukemia, Vol. 33, Núm. 5, pp. 1256-1267
2018
-
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia
British Journal of Haematology
-
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study
Haematologica, Vol. 103, Núm. 7, pp. 1209-1217
-
Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis
Leukemia
-
Prognostic risk models for transplant decision-making in myelofibrosis
Annals of Hematology, Vol. 97, Núm. 5, pp. 813-820
2017
-
Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis
European Journal of Haematology, Vol. 98, Núm. 4, pp. 407-414
2016
-
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
British Journal of Haematology, Vol. 172, Núm. 5, pp. 786-793
2015
-
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
Annals of Hematology, Vol. 94, Núm. 6, pp. 911-918
2014
-
Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?
American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211